While overall the group of patients treated with NAT displayed less cortical atrophy than patients receiving DMF, the DMF-treated patients free of disease activity with a stronger depletion of CD8+ T cells showed even less GM loss in comparison to the NAT-treated patients. The gene discussed is BRD2; the disease is Cerebral cortical atrophy.